Vimarsana
Biggest News Aggregation in the World

Page 2 - Including Stroke News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Including Stroke. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Including Stroke Today - Breaking & Trending Today

Alkermes plc: Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress - Vimarsana News

Alkermes plc: Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress

? Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference ? DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced

Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society - Vimarsana News

Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International...

Alkermes plc: Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society - Vimarsana News

Alkermes plc: Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society

- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented

New Study Finds Link Between Excessive Drinking and Afib Episodes - Vimarsana News

New Study Finds Link Between Excessive Drinking and Afib Episodes

More ER visits for atrial fibrillation were found on days such as New Year’s, Christmas, and Super Bowl Sunday.

AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder - Vimarsana News

AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating...